Plaque Psoriasis

At Week 52, icotrokinra achieved clear/almost clear skin in 72% of patients with scalp psoriasis and 85% with genital psoriasis, with consistent safety and durable responses.

This systematic review and meta-analysis highlights tildrakizumab’s efficacy in Asian patients versus the efficacy of other biologic options.

This conference preview for the 2025 Fall Clinical Dermatology meeting highlights upcoming sessions and interviews.

A study found no major differences in overall cancer risk among adalimumab, secukinumab, and ustekinumab for psoriasis.

SelectION, Inc. has announced positive topline findings from its phase 1b proof-of-concept study assessing si-544 in those with psoriasis vulgaris.

JAK inhibitors have transformed the world of treatment for inflammatory disease, and views on their safety and efficacy have also transformed over the years.

This systematic review and meta-analysis of available randomized controlled trials compared biologics for psoriasis, such as ixekizumab, secukinumab, and ustekinumab.

Panelists discuss how emerging TYK2 inhibitors such as brepocitinib and ESK001 target the JAK/STAT pathway to block IL-23 and IL-17 signaling, showing promising phase 2 results with PASI 100 rates around 33% and PASI 75 rates of 64%.

In this analysis, investigators validated the Automatic Psoriasis Area and Severity Index (APASI), an AI-driven system for psoriasis severity assessment.

Panelists discuss how effective shared decision-making involves clinicians presenting 2 to 3 optimal treatment options based on patient-specific factors rather than overwhelming patients with all possibilities or making unilateral decisions, ultimately improving treatment adherence.

Panelists discuss how many eligible patients with psoriasis remain undertreated despite advanced therapy availability due to patient discontinuation from topical burden, injection anxiety, and the historical lack of effective oral options with good safety profiles.

In this analysis, investigators highlight the impact of the route of MTX administration on drug survival among patients with psoriasis.

These data highlight secukinumab’s potential as a treatment to provide enhanced psychological outcomes among those with psoriasis.

This study highlighted tildrakizumab’s use in daily practice within a heterogeneous cohort of patients with psoriasis commonly affected by comorbid conditions.

Panelists discuss how modern topical treatments have evolved beyond traditional corticosteroids to include more effective nonsteroidal options, such as tapinarof and roflumilast, which provide better long-term control and can complement systemic therapies.

Panelists discuss how plaque psoriasis affects 0.4% to 8% of the global population, with high-impact areas such as the scalp (up to 80% of patients) and nails (25% of patients) significantly impacting quality of life and warranting systemic therapy consideration.

This review of the month of September highlights some of the most significant dermatology headlines.

This review of Q3 developments in the dermatology space highlight a number of significant news stories from 2025.

During this EADV interview, Lebwohl speaks to some of the most recent developments in the psoriasis research space.

This EADV 2025 interview featuring Linda Stein Gold, MD, highlights her team’s findings on icotrokinra versus placebo and versus deucravacitinib in psoriasis.

This interview at EADV 2025 features Mona Shahriari, MD, who highlighted recent findings on the drugs icotrokinra and povorcitinib in dermatology.

A compilation of 14 trials presented as late-breaking data at EADV 2025 Congress.

New findings from the POSITIVE trial highlight tildrakizumab's effectiveness in enhancing quality of life for psoriatic disease patients.

Based on 3 propensity-matched control groups, patients with psoriasis can have anywhere from a 40% to 56% higher risk.